CytomX Therapeutics

General Information

We are an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on our Probody technology platform. We are using our platform to create proprietary cancer immunotherapies against clinically-validated targets as well as to develop first-in-class cancer therapeutics against novel targets. We believe that our Probody platform will allow us to improve the combined efficacy and safety profile, or therapeutic window, of monoclonal antibody modalities including cancer immunotherapies, antibody drug conjugates (“ADCs”) and T-cell-recruiting bispecific antibodies. Our Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. We are currently developing Probody therapeutics that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, such as CD-166, that are difficult to drug and lead to concerns about damage to healthy tissues, or toxicities. In addition to our proprietary programs, we are collaborating with strategic partners including Bristol-Myers Squibb Company (“BMS”), Pfizer Inc. (“Pfizer”) and ImmunoGen, Inc. (“ImmunoGen”) to develop selected Probody therapeutics.

Employees: 61
Founded: 2008
Contact Information
Address 343 Oyster Point Blvd., Suite 100, South San Francisco, CA 94080
Phone Number (650) 515-3185
Web Address
View Prospectus: CytomX Therapeutics
Financial Information
Market Cap $418.8mil
Revenues $7.6 mil (last 12 months)
Net Income $-25.9 mil (last 12 months)
IPO Profile
Symbol CTMX
Exchange NASDAQ
Shares (millions): 6.7
Price range $12.00 - $12.00
Est. $ Volume $80.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Jefferies/ Cowen and Company
CO-Managers Oppenheimer & Co.
Expected To Trade:
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change